

Adverse effects of the new generation of Rotavirus vaccine in Egyptian infants

**Thesis submitted for partial fulfillment of
Master Degree in Pediatrics**

Presented by

**May Mohamed Fahmy
M.B.B.CH**

Faculty of Medicine- Ain Shams University

Supervised by

**Prof. Dr. Nancy Abdelaziz Soliman
Professor of Pediatrics,
*Ain Shams University***

**Prof. Dr. Maha El-Gaafary
Professor of Community Medicine,
*Ain Shams University***

2013

﴿وَقُلْ رَبِّ زِدْنِي عِلْمًا﴾

سورة طه الآية (١١٤)

Acknowledgment

In the name of Allah, most gracious, most merciful.

First & foremost I would like to dedicate this thesis to the memory of my Father who is a constant source of inspiration.

I hope he would have been proud.

I offer my sincerest gratitude to my supervisors,

Prof. Dr. Nancy Abdelaziz Soliman Professor of Pediatrics, Ain Shams University, who have supported me throughout my thesis with her patience, advice & guidance. And Special thanks and respect to Dr Maha El-Gaafary Professor of Community Medicine, for her invaluable help & assistance to finish the this thesis.

And Last but not the least; I would like to thank my husband, my lovely daughters & family members for supporting & encouraging me to pursue this degree.

List of contents

<i>List of abbreviation</i>		I
<i>List of figures</i>		III
<i>List of tables</i>		V
<i>Introduction & Aim of work</i>		1
<i>Review of literature</i>		
	<i>Rotavirus</i>	4
	<i>Rotavirus vaccines</i>	34
	<i>Rotarix</i>	47
<i>Subjects and methods</i>		61
<i>Results</i>		63
<i>Discussion</i>		96
<i>Summary</i>		102
<i>Conclusion</i>		104
<i>Recommendations</i>		105
<i>References</i>		106
الملخص العربي		١٣١
<i>Appendix</i>		

List of abbreviations

ACIP: Advisory Committee for Immunization Practices

CDC: Centers for Disease Control

EIA: enzyme immunoassay

FDA: *Food and Drug Administration*

GAVI Alliance: The Global Alliance for Vaccines and Immunizations

NA: Neutralizing Antibodies

NCDDP: National Clinical Dataset Development Programme

NICU: neonatal intensive care unit

NSP: Non-Structural proteins

ORS: oral rehydration solution

PATH: The Pan American Health Organization

RVGE: Rotavirus gastroenteritis

RNA: Ribo-nucleic Acid

RT-PCR: Reverse Transcription–Polymerase Chain Reaction

VAERS: Vaccine Adverse Event Reporting System

VSD: Vaccine Safety Datalink

List of figures

<i>Figure</i>	<i>Title</i>	<i>Page</i>
(1)	Schematic representation of the rotavirus	11
(2)	Classification of rotaviruses, modification	13
(3)	Level of education of studied parents	64
(4)	The occupation of parents shared in the study	65
(5)	Residence of parents participated in the study	66
(6)	Number of full term & preterm babies included in the study	67
(7)	Age of infants and children included in the study	68
(8)	Health problems of studied infants and children	69
(9)	Number of breast fed and bottle fed included in the study	70
(10)	Last feeding before vaccination	71
(11)	Symptoms at time of feeding	72
(12)	Type of previous vaccination	73
(13)	Number of cases received other vaccines at the same time of receiving Rotavirus vaccine	74
(14)	Gastrointestinal side effects	75
(15)	Neurological side effects	76

(16)	Comparison between full term and preterm infants included in the study regarding the side effects	78
(17)	Comparison between breast feeding and bottle feeding regarding the side effects	80
(18)	Age of baby and side effects	82
(19)	Comparison between GIT side effects after 1st and 2nd dose of the vaccine	84
(20)	Comparison between Neurological side effects after 1st and 2nd dose of the vaccine	85
(21)	Comparison between fever & URTI after 1st and 2nd dose of the vaccine	87
(22)	Comparison between types of vaccination received at the same time with Rotarix	89
(23)	Comparison between types of vaccination received before Rotarix	91
(24)	Time of feeding before Rotarix and frequency of side effects	93
(25)	GIT side effects among infants with history of GIT disorders	94

List of tables

<i>Table</i>	<i>Title</i>	<i>Page</i>
(1)	Characteristics of the major efficacy trials of Rotarix® (RV1)	49
(2)	Level of education of studied parents	63
(3)	The occupation of parents shared in the study	64
(4)	Residence of parents participated in the study	65
(5)	Number of full term & preterm babies included in the study	66
(6)	Age of infants and children included in the study	67
(7)	Health problems of studied infants and children	68
(8)	Number of breast fed and bottle fed included in the study	69
(9)	Last feeding before vaccination	70
(10)	Symptoms at time of feeding	71
(11)	Type of previous vaccination	72
(12)	Number of cases received other vaccines at the same time of receiving Rotavirus vaccine	73
(13)	Gastrointestinal side effects	74
(14)	Neurological side effects	75
(15)	Comparison between full term and	77

	preterm infants included in the study	
(16)	Comparison between breast feeding and bottle feeding regarding the side effects	79
(17)	Age of baby and GIT side effects (%)	81
(18)	Comparison between GIT side effects after 1st and 2nd dose of the vaccine	83
(19)	Comparison between Neurological side effects after 1st and 2nd dose of the vaccine	85
(20)	Comparison between fever & URTI after 1st and 2nd dose of the vaccine	86
(21)	Comparison between type of fever after the 1st and 2nd dose of vaccination	86
(22)	Comparison between types of vaccination received at the same time with Rotarix	88
(23)	Comparison between types of vaccination received before Rotarix	90
(24)	Time of feeding before Rotarix and frequency of side effects	92
(25)	Number of parents approving the price of the vaccine	94
(26)	Parents opinion about the age limit of the vaccine	95
(27)	Parents opinion acceptance of an oral vaccine	95

Introduction

Diarrheal disease continues to be one of the leading health problems in the world & may account for as many as 4.5 to 5 million death per year in children less than 5years old in developing countries (*walker et al., 1994*).

Throughout the world, Rotaviruses are the single most important etiological agents causing severe diarrhea in infants & children with the 1st 5year of their life (*kopithion et al., 2001*).

Acute infantile diarrhea is the leading cause of death among Egyptian children, accounting for more than 90%of the death in children less than 2years. In Egypt, with its population of about 60 million in 1995, 10% are children under 5years. A child under 5years suffers an average 3 bouts of acute diarrhea yearly (*NCDDP, 1996*).

Speaking of diarrheal disease, it is one of the leading problems in the world & it is the commonest cause of morbidity among Egyptian infants (*Gaber, 1990*).

Because of the high burden of disease in both developed and developing countries, the need for an effective vaccine against the disease has been recognized by the Centers for Disease Control and Prevention, the World Health Organization (WHO) (*Cunliffe et al., 1998*), PATH, the Pan American Health Organization, and the GAVI Alliance (formerly known as the Global Alliance for Vaccines and Immunizations). There are 2 newly licensed rotavirus vaccines and several vaccines still under development (*Dennehy, 2005*).

The *Rotarix*TM vaccine, a live-attenuated vaccine, strategy is based on evidence from studies indicating that the first two natural human rotavirus infections protect against subsequent severe rotavirus illness, and provide heterotypic protection against multiple rotavirus strains (*Velazquez et al., 1996*).

Aim of work

The aim of the study is to study the prevalence of the common side effects of ROTARIX vaccine and its implication on parents' satisfaction in Egypt during the period from February 2009 till October 2010, through a questionnaire answered by the parents to follow up vaccinated infants and children and to know parents' opinion about the vaccine.

Rotavirus

Epidemiology

Rotavirus infection is the most common cause of severe diarrhea globally, resulting in an estimated 114 million episodes of gastroenteritis, 24 million outpatient visits, and 2.4 million hospitalizations each year (*Glass et al., 1996*).

In total, there were over 500,000 deaths attributed to rotavirus in 2004, resulting in 5% of all deaths in children, 5 years of age (*Dennehy et al., 2008; Parashar et al., 2009*). The rate of rotavirus illness is similar in both developed and developing countries; in all settings, rotavirus is responsible for approximately 39% of hospitalizations due to diarrhea regardless of a country's income status (*Parashar, 2006*).

However, the burden of mortality is almost entirely in developing countries where access to care is limited and risk factors for disease are high. Every year, greater than

86% of deaths occur in Asia and sub-Saharan Africa, whereas less than 1,000 rotavirus deaths occur in high-income countries (*Parashar et al., 2009*).

Rotavirus gastroenteritis occurs almost exclusively in infants and children, with nearly every child having been infected by the age of 5 years (*Bernstein et al., 2009*). The majority of serious infections occur between 4 and 24 months of age, although the peak age of serious disease varies globally (*Podewils et al., 2004*). In developing countries, the mean age of symptomatic rotavirus infection is between 6 and 9 months while industrialized countries have a median age between 9 and 15 months (*Bresee et al., 1999*).

Older children are protected from serious disease by previous exposure and apparent infection: if it occurs, it is usually mild (*Velazquez et al., 1996*). Similarly, disease can occur in neonates but is typically mild or asymptomatic due to protection from maternal antibodies (*Glass et al., 2005*).

Rotavirus infection shows strong seasonal variation; in temperate high-income countries, rotavirus disease occurs most often during the winter, whereas seasonality is less pronounced in tropical and low-income countries (*Bresee et al., 1999*).

Differences between developed and devevoping countries:

Although the incidence of Rotavirus in developed and developing countries is similar,

These are significant difference in term of:

- The age, at which significant infection first occur
- Seasonality of virus, circulationand that's linked to difference in climate,
- Serotype prevalence,
- Data on the cost of the disease, which is not readily available in many developing countries,
- Mortality